ライフサイエンスコーパス: area under the concentration-time curve

1 aximum observed plasma concentration and the area under the concentration-time curve.

2 was measured as the ratio of vCSF-to-plasma area under the concentration-time curves.

3 apentine recipients who had high rifapentine areas under the concentration-time curve.

4 he paclitaxel peak plasma concentrations and areas under the concentration-time curve.

5 e; 14%, P < 0.01, female mice) and increased area under the concentration-time curve (25%, P < 0.05,

6 ertuzumab (docetaxel 75 mg/m(2); carboplatin area under the concentration-time curve 6 mg/mL x min; t

7 Patients received either carboplatin (area under the concentration-time curve, 6) and paclitax

8 ed paclitaxel (225 mg/m(2)) and carboplatin (area under the concentration-time curve, 6).

9 Plasma CA4P and CA4 area under the concentration-time curve and maximal conc

10 PKs (area under the concentration-time curve and maximum meas

11 Area under the concentration-time curve, and peak serum

12 een micafungin efficacy and the ratio of the area under the concentration-time curve, and the optimal

13 (C(av)), i.e., the dosing interval-corrected area under the concentration-time curves, and >/=36% for

14 A dose of 300 mg/m(2) achieved an area under the concentration-time curve associated with

15 rh-Endo pharmacokinetic profiles achieved area under the concentration-time curves associated with

16 The AF area under the concentration-time curve at 12 hours was

17 ty was noted in vorinostat disposition, with area under the concentration-time curves at 230 mg/m(2)/

18 in 35 fractions) with weekly carboplatin at area under the [concentration-time] curve (AUC) 2 and si

19 0 mg/m(2) on days 1 and 8 and carboplatin at area under the [concentration-time] curve (AUC) 5.0 or 4

20 The area under the concentration time curve (AUC +/- SE) for

21 eventeen patients received carboplatin at an area under the concentration time curve (AUC) of 6 for s

22 In a multiple regression model, MTX area under the concentration time curve (AUC)0-48h incre

23 as determined as the ratio of NG/intravenous area under the concentration-time curve (AUC infinity )

24 k of importance, were a pyrazinamide 24-hour area under the concentration-time curve (AUC) </= 363 mg

25 r infusion on day 1 followed by carboplatin, area under the concentration-time curve (AUC) 5 (cohort

26 ction paclitaxel 175 mg/m(2) and carboplatin area under the concentration-time curve (AUC) 6 for two

27 ositive screens were confirmed by population-area under the concentration-time curve (AUC) analysis.

28 Linear increases in the area under the concentration-time curve (AUC) and Cmax w

29 BI was the product of total CPT-11 area under the concentration-time curve (AUC) and the re

30 Efavirenz decreased faldaprevir area under the concentration-time curve (AUC) by 35%, Cm

31 Following 30-mg/m2 doses, the ATRA area under the concentration-time curve (AUC) decreased

32 The first-cycle plasma area under the concentration-time curve (AUC) did not co

33 with CYP3A5 nonexpressors, the average blood area under the concentration-time curve (AUC) for AM19 a

34 between dose, peak plasma concentration, and area under the concentration-time curve (AUC) for both C

35 The area under the concentration-time curve (AUC) for CsA an

36 n of maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC) for each p

37 The maximum concentration Cmax and area under the concentration-time curve (AUC) for O6-Ben

38 tory tests examined, BUN yielded the highest area under the concentration-time curve (AUC) for predic

39 eakfast produced mean increases in lapatinib area under the concentration-time curve (AUC) of 167% (2

40 oncurrent chemoradiotherapy with carboplatin area under the concentration-time curve (AUC) of 2 and p

41 as a 24 hour infusion and carboplatin at an area under the concentration-time curve (AUC) of 5 to 6

42 mg/m2 by 1-hour infusion, carboplatin at an area under the concentration-time curve (AUC) of 5.0, an

43 fusion on day 1, carboplatin at an estimated area under the concentration-time curve (AUC) of 6.0 on

44 The mean area under the concentration-time curve (AUC) of 8-oxo-O

45 ion (Cmax) of 5.97 +/- 2.25 microg/mL and an area under the concentration-time curve (AUC) of 811.4 +

46 stinguishing active TB from pneumonia had an area under the concentration-time curve (AUC) of 96.5% (

47 The serum exposure to BV as measured by area under the concentration-time curve (AUC) seemed to

48 pin (1 mg/kg), a 1.7-fold increase in plasma area under the concentration-time curve (AUC) was observ

49 Maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC) were compa

50 The geometric mean (GM) of raltegravir area under the concentration-time curve (AUC)(0-12h) and

51 ime-corrected (tau, hours) expression of the area under the concentration-time curve (AUC), i.e., Cav

52 ation-control CsA regimens based upon either area under the concentration-time curve (AUC; n=412 pati

53 ntration, time to maximum concentration, and area under the concentration/time curve (AUC) were deter

54 der actual-use conditions and calculated the area-under-the-concentration-time curve (AUC) to assess

55 ree or four cycles of high-dose carboplatin (area under the concentration-time curve [AUC] 16), pacli

56 vir decreased the exposure of all PI/r, with area under the concentration-time curve [AUC] from time

57 rboplatin on day 2 (300 mg/m2 or dosed to an area under the concentration-time curve [AUC] of 6 mg/mL

58 s model in relation to rifapentine exposure (area under the concentration-time curve [AUC]).

59 ed multiple cycles of high-dose carboplatin (area under the concentration-time curve [AUC], 12 to 20)

60 ximab PK and calculating rituximab exposure (area under the concentration-time curve; AUC).

61 /-0.37 microg/ml, respectively, with a 24-hr area under the concentration time curve (AUC0-24) of 24.

62 ence interval [CI], .46-.66) for the 24-hour area under the concentration-time curve (AUC0-24h); 0.65

63 se, children achieve different 0- to 24-hour area under the concentration-time curves (AUC0-24) becau

64 than adults and achieve lower 0- to 24-hour area under the concentration-time curves (AUC0-24).

65 bitory concentrations (MICs) required higher area under the concentration time curves (AUCs) to achie

66 Although the maternal plasma area under the concentration-time curves (AUCs) of GLB i

67 glomerular filtration rate + 25)], to target areas under the concentration time curve (AUCs) of 5, 7,

68 sampled for pharmacokinetic studies, and the area under the concentration-time curve (AUCtau) and ave

69 Dose, peak concentration, and area under the concentration-time curve correlated with

70 ekly isoniazid/rifapentine (median isoniazid area under the concentration-time curve for 12 hours aft

71 The area under the concentration-time curve for hourly corti

72 allows delineation of target drug exposures (area under the concentration/time curve for 24 h : minim

73 examined the influence of therapy intensity (area under the concentration/time curve for 24 h:minimum

74 Lapatinib dosage was related linearly to area under the [concentration-time] curve from start tim

75 In vivo, the peak plasma concentration and area under the concentration time curve from 0 to 8 hour

76 of the moxifloxacin-free (non-protein-bound) area under the concentration-time curve from 0 to 24 h t

77 riation [CV], approximately 40%) in Cmax and area under the concentration-time curve from 0 to 24 hou

78 The area under the concentration-time curve from 0 to 24 hou

79 analysis demonstrated that the lenalidomide area under the concentration-time curve from 0 to 24 hou

80 Concomitant boceprevir increased the area under the concentration-time curve from time 0 to i

81 The area under the concentration-time curve further increase

82 atients, using Calvert's formula [dose(mg) = area under the concentration time curve (glomerular filt

83 The area under the concentration-time curve increased linear

84 Drug exposure (area under the concentration-time curve) is dose proport

85 ildren <3 years old, isoniazid 0- to 24-hour area under the concentration-time curve <11.95 mg/L x ho

86 After RTV was withdrawn, the TVR AUC(0-12) (area under the concentration-time curve), maximum concen

87 0084) and area under the concentration-time curve (median 36 v 23

88 amplify resistant subpopulation at day 4-5 (area under the concentration-time curve/minimum inhibito

89 and carboplatin (at a dose equivalent to an area under the concentration-time curve of 2) on days 1

90 nistration of higher cumulative doses (total area under the concentration-time curve of 3049 ng day/m

91 on days 1 and 8, carboplatin at an estimated area under the concentration-time curve of 5 mg min/mL i

92 ravenous dose once every 21 days at a target area under the concentration-time curve of 6 mg/mL.min.

93 beta-lap-dC3 micelles correlated with higher area under the concentration-time curves of beta-lap in

94 ciclovir in this population, a target AUC12 (area under the concentration-time curve over a 12-h peri

95 Area under the concentration-time curve (tau) and maximu

96 re/relapse, a drug with consistently greater area under the concentration-time curve than isoniazid m

97 CRA/IFNalpha increases TAX area under the concentration-time curve through an inhib

98 bial kill was best explained by the ratio of area under the concentration-time curve to minimum inhib

99 e in TAX clearance and a 23% decrease in the area under the concentration-time curve values of the TA

100 Area-under-the concentration-time curve was a better pre

101 The sum of temsirolimus and sirolimus areas under the concentration-time curve was comparable

102 concentration (Cmax), and sirolimus Cmax and area under the concentration-time curve were decreased i

103 trated that midazolam half-life, C(max), and area under the concentration-time curve were increased,

104 Dose-related linear increases in area under the concentration-time curve were seen on day

105 es in both maximum plasma concentrations and area under the concentration-time curve, while the agent

106 es in clearance, maximum concentrations, and areas under the concentration-time curves, with constant